Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionGuggenheim Capital Llc
Latest Disclosed Ownership38,866 shares
Latest Disclosed Value $ 5,120,206
Guggenheim Capital Llc reports 61.65% increase in ownership of NBIX / Neurocrine Biosciences, Inc.

On May 15, 2026 - Guggenheim Capital Llc filed a 13F-HR form disclosing ownership of 38,866 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $5,120,206 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 24,043 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of 61.65% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 38,866 14,823 61.65 5,120 50.15 0.0198
2026-02-17 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 24,043 1,755 7.87 3,410 9.02 0.0244
2025-11-13 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 22,288 -636 -2.77 3,129 8.57 0.0227
2025-08-13 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 22,924 -1,355 -5.58 2,881 7.30 0.0229
2025-05-14 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 24,279 1,381 6.03 2,685 -14.08 0.0247
2025-02-13 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 22,898 -9,134 -28.52 3,126 -15.31 0.0253
2024-11-13 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 32,032 -18,115 -36.12 3,691 -46.54 0.0258
2024-08-14 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 50,147 12,629 33.66 6,904 33.42 0.0490
2024-05-14 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 37,518 8,579 29.65 5,174 35.69 0.0365
2024-02-14 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 28,939 -10,169 -26.00 3,813 -13.32 0.0288
2023-11-14 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 39,108 -5,188 -11.71 4,400 5.31 0.0378
2023-08-11 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 44,296 2,415 5.77 4,177 -1.46 0.0328
2023-05-11 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 41,881 -265 -0.63 4,239 -15.78 0.0357
2023-02-14 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 42,146 -1,351 -3.11 5,034 8.94 0.0442
2022-11-14 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 43,497 -3,782 -8.00 4,620 0.26 0.0423
2022-08-15 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 47,279 -10,003 -17.46 4,608 -14.19 0.0364
2022-05-16 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 57,282 -4,900 -7.88 5,370 1.40 0.0323
2022-02-14 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 62,182 3,449 5.87 5,296 -5.98 0.0276
2021-11-15 2021-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 58,733 -1,322 -2.20 5,633 -3.63 0.0338
2021-08-13 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 60,055 9,106 17.87 5,845 17.96 0.0344
2021-05-13 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 50,949 12,056 31.00 4,955 32.91 0.0325
2021-02-16 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 38,893 352 0.91 3,728 0.59 0.0234
2020-11-13 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 38,541 -5,981 -13.43 3,706 -31.77 0.0268
2020-08-14 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 44,522 4,185 10.38 5,432 55.60 0.0420
2020-06-02 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 40,337 -8,860 -18.01 3,491 -33.98 0.0352
2020-02-20 2019-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 49,197 7,896 19.12 5,288 42.07 0.0397
2020-02-14 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 49,197 7,896 5,288 31,340.9190
2020-02-20 2019-09-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 41,301 -8,776 -17.53 3,722 -11.97 0.0297
2019-11-14 2019-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 41,301 -8,776 3,722 27,275.9078
2019-08-14 2019-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 50,077 -6,910 -12.13 4,228 -15.79 0.0344
2019-05-15 2019-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 56,987 404 0.71 5,021 24.25 0.0409
2019-02-14 2018-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 56,583 5,190 10.10 4,041 -36.05 0.0342
2018-11-14 2018-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 51,393 -4,330 -7.77 6,319 15.44 0.0412
2018-08-14 2018-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 55,723 -2,592 -4.44 5,474 13.19 0.0365
2018-05-15 2018-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 58,315 -7,540 -11.45 4,836 -5.38 0.0118
2018-02-14 2017-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 65,855 -26,490 -28.69 5,111 -9.67 0.0121
2017-11-14 2017-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 92,345 -4,140 -4.29 5,658 27.46 0.0133
2017-08-14 2017-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 96,485 7,720 8.70 4,439 15.51 0.0118
2017-05-15 2017-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 88,765 6,620 8.06 3,843 20.89 0.0104
2017-02-14 2016-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 82,145 -6,420 -7.25 3,179 -29.12 0.0091
2016-11-14 2016-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 88,565 -10,442 -10.55 4,485 -0.33 0.0140
2016-08-15 2016-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 99,007 -17,365 -14.92 4,500 -2.24 0.0141
2016-05-16 2016-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 116,372 -29,123 -20.02 4,603 -44.08 0.0145
2016-02-16 2015-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 145,495 -48,205 -24.89 8,231 6.80 0.0240
2015-11-16 2015-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 193,700 -37,622 -16.26 7,707 -30.24 0.0237
2015-08-14 2015-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 231,322 12,960 5.94 11,048 27.41 0.0273
2015-05-18 2015-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 218,362 16,145 7.98 8,671 91.92 0.0205
2015-05-15 2015-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 218,362 8,671
2015-02-17 2014-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 202,217 8,032 4.14 4,518 48.47 0.0113
2014-11-14 2014-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 194,185 4,458 2.35 3,043 8.06 0.0073
2014-08-14 2014-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 189,727 -36,403 -16.10 2,816 -22.66 0.0071
2014-05-16 2014-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 226,130 -27,244 -10.75 3,641 53.82 0.0104
2014-02-14 2013-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 253,374 -4,218 -1.64 2,367 -18.83 0.0072
2013-11-14 2013-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 257,592 257,592 2,916 0.0105
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.